HI,欢迎来到学术之家,发表咨询:400-888-7501  订阅咨询:400-888-7502  股权代码  102064
0

S6A-2 Neurocognitive Impairment in Schizophrenia:Clinical Correlates and Pathophysiological Mechanisms

作者:张向阳neuropsychologicalstatusmatricsconsensuscognitive

摘要:Background:Cognitive deficits in learning,memory,attention,executive functioning,spatial working memory and cognitive processing speed are core features of schizophrenia,which may be associated with clinical variables.However,the pathological mechanisms of cognitive deficits in schizophrenia are still unclear.We have investigated the demographic and clinical characteristics that may be related to cognitive deficits and their possible underlying mechanism in schizophrenia.Methods:We examined the cognitive functions in both chronic medicated and first-episode drug-nave schizophrenia patients versus healthy controls by using the Repeatable Battery for the Assessment of Neuropsychological Status(RBANS)or the MATRICS Consensus Cognitive Battery(MCCB).We assessed patient psychopathology using the Positive and Negative Syndrome Scale.At the same time,some biomarkers in serum and the related gene polymorphisms were measured in both groups.Results:We found significantly lower cognitive scores on the RBANS or MCCB total score and mostly of their subscales in both chronic and first-episode patients than healthy controls.Compared to first-episode patients,chronic patients displayed worse cognitive performance in some domains.Some clinical variables,such as clinical symptoms,tardive dyskinesia,smoking,and comorbid diabetes were associated with cognitive impairments in schizophrenia patients.Meanwhile,some biomarkers such as BDNF,cytokine,and free radical parameters were found to be associated with cognitive deficits in patients.Also,some gene polymorphisms,such as BDNF and MnSOD were also involved in cognitive deficits in patients.Conclusions:The extensive compromised cognition is present in the early stage of schizophrenia,some of which could be more severe in the chronic stage of illness.Some demographic and clinical variables are risk factors for cognitive deficits in schizophrenia.Some biomarkers may play important roles for the cognitive impairments in schizophrenia.

注:因版权方要求,不能公开全文,如需全文,请咨询杂志社

神经药理学报

《神经药理学报》(CN:13-1361/R)是一本有较高学术价值的大型双月刊,自创刊以来,选题新奇而不失报道广度,服务大众而不失理论高度。颇受业界和广大读者的关注和好评。 《神经药理学报》内容涉及神经解剖学、神经生物学、神经生理学等领域,报道与神经系统疾病发病机制及其治疗相关的中药有效成分、天然药物化学、药物分析学、分子生物学、药剂学及毒理学方面的研究论著,具有前沿性、创新性、科学性、实用性的特点,及时、快速反映神经药理学最新科研成果和研究进展。

杂志详情